

**Title of Resource:** *Lupus: Patient Voices*

**Authors:**

- Lupus and Allied Diseases Association: Kathleen A. Arntsen
- Lupus Foundation of America: Pat Wildman
- Lupus Research Alliance: Diane Gross
  
- Consultants:
  - o Faegre Baker Daniels Consulting: Dave Zook, Lauren Bloch
  - o Hyman, Phelps & McNamara, P.C.: James E. Valentine
  - o YourEncore: Tim Franson

**Disclosures:** The Lupus and Allied Diseases Association, the Lupus Foundation of America, and the Lupus Research Alliance receive funding from pharmaceutical companies in the form of sponsorship of programs and events. David Zook and Lauren Bloch are employed by Faegre Baker Daniels LLC, a law and consulting firm that represents sponsors developing drugs and patient advocacy organizations. James Valentine is employed by Hyman, Phelps & McNamara, P.C., a law firm that represents sponsors developing drugs and patient advocacy organizations. Tim Franson, M.D. is Chief Medical Officer of YourEncore, a consulting and staffing company and also affiliated with Faegre Baker Daniels Consulting, both of which work with sponsors developing therapies and with patient organizations. Franson is also a member of the Board of Directors for the Critical Path Institute, the US Pharmacopeia, Paratek Pharmaceuticals and Cidara Therapeutics. Other individual authors have nothing to disclose.

**Funding:** The Lupus Patient-Focused Drug Development Meeting was designed and implemented entirely by the Lupus and Allied Diseases Association, the Lupus Foundation of America, and the Lupus Research Alliance. The resulting *Lupus: Patient Voices* Report also was prepared by these organizations. Sponsorship of the meeting was provided by Aurinia Pharmaceuticals, the Biotechnology Innovation Organization, Bristol-Myers Squibb, Eli Lilly and Company, EMD Serono, Genentech, GlaxoSmithKline, Mallinckrodt Pharmaceuticals, and UCB. These funds were used to secure meeting space and to support other logistical and consulting services for the initiative. The Lupus and Allied Diseases Association, the Lupus Foundation of America, and the Lupus Research Alliance explicitly state that the sponsoring companies had no control over the meeting content or related activities.

**Version Date:** March 6, 2018

**Revisions and Modifications:** This document has not been revised and/or modified after the version date listed above.

The submitters have received all necessary permissions to submit this external resource to the FDA. Linking to this resource from the FDA website does not violate the proprietary rights of others.

**Points of Contact:**

- Kathleen A. Arntsen, Lupus and Allied Diseases Association, [kathleen@ladainc.org](mailto:kathleen@ladainc.org)
- Pat Wildman, Lupus Foundation of America, [wildman@lupus.org](mailto:wildman@lupus.org)
- Diane Gross, Lupus Research Alliance, [dgross@lupusresearch.org](mailto:dgross@lupusresearch.org)